NCT06892691 Pleuroscopy First Versus Thoracentesis First in Patients With Suspected Malignant Pleural Effusions
| NCT ID | NCT06892691 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Icahn School of Medicine at Mount Sinai |
| Condition | Pleural Effusion |
| Study Type | INTERVENTIONAL |
| Enrollment | 98 participants |
| Start Date | 2025-03-24 |
| Primary Completion | 2026-09-17 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 98 participants in total. It began in 2025-03-24 with a primary completion date of 2026-09-17.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a randomized control trial of patients with suspected malignant pleural effusions to compare whether patients who have a thoracentesis or pleuroscopy (pleural biopsy) obtain an adequate biopsy, achieve a diagnosis, and begin cancer-directed therapy faster.
Eligibility Criteria
Inclusion Criteria: * Referral for diagnostic pleural procedure. * Age ≥ 18 years. * Suspected malignant pleural effusion (Suggestive radiologic appearance (based on computed tomography or positron emission tomography) OR suspected cancer with associated effusion.) Exclusion Criteria: * Inability to provide informed consent. * Needs emergent drainage. * Pleural effusion is known to be malignant. * Suspected transudative, infectious or inflammatory effusion etiology. * Having prior inconclusive/non-diagnostic thoracentesis or pleuroscopy. * Patient is deemed by the clinical team to be more appropriate for VATS biopsy. * Terminally ill patients in whom a diagnosis will not change management, or who is unlikely to be a candidate for oncological treatment due to significant comorbidities. * Pregnancy
Contact & Investigator
Udit Chaddha, MBBS
PRINCIPAL INVESTIGATOR
MOUNT SINAI HOSPITAL
Frequently Asked Questions
Who can join the NCT06892691 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pleural Effusion. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06892691 currently recruiting?
Yes, NCT06892691 is actively recruiting participants. Contact the research team at udit.chaddha@mssm.edu for enrollment information.
Where is the NCT06892691 trial being conducted?
This trial is being conducted at New York, United States, New York, United States.
Who is sponsoring the NCT06892691 clinical trial?
NCT06892691 is sponsored by Icahn School of Medicine at Mount Sinai. The principal investigator is Udit Chaddha, MBBS at MOUNT SINAI HOSPITAL. The trial plans to enroll 98 participants.